Chris Doyle

Chris is Director of IBC Services and an IBC Chair at WCG, roles in which he works with clinical trial sites, sponsors, and CROs to ensure research involving human gene transfer is conducted safely. Prior to joining WCG in early 2018, Chris was a research fellow at the Albert Einstein College of Medicine (Bronx, NY), where he explored novel mechanisms of antibody activity against Streptococcus pneumoniae.

Chris received his BA in Biology from Assumption College (Worcester, MA) in 2008 and his PhD in Molecular Genetics and Microbiology from Stony Brook University (Stony Brook, NY) in 2014, where he studied the pathogenesis of Francisella tularensis in a high containment Biosafety Level 3 laboratory. Chris has authored a number peer-reviewed publications describing his past research, frequently speaks about gene therapy, biosafety, and IBCs, and is a member of the American Society for Microbiology (ASM) and the American Biological Safety Association (ABSA).